NGNE
Neurogene Inc.NASDAQHealthcare$20.69-1.06%ClosedMarket Cap: $322.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.20
P/S
0.00
EV/EBITDA
-2.50
DCF Value
$4.36
FCF Yield
-24.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-33.0%
ROA
-31.2%
ROIC
-37.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-27.5M | $-24.7M | $-1.60 | — |
| FY 2025 | $0.00 | -Infinity% | $-103.2M | $-90.4M | $-4.24 | — |
| Q3 2025 | $0.00 | NaN% | $-23.8M | $-21.0M | $-0.99 | — |
| Q2 2025 | $0.00 | NaN% | $-26.1M | $-22.0M | $-1.05 | — |
| Q1 2025 | $0.00 | NaN% | $-25.9M | $-22.6M | $-1.08 | — |
| Q4 2024 | $0.00 | -Infinity% | $-21.5M | $-19.5M | $-1.31 | — |
| FY 2024 | $925.0K | -251.0% | $-82.6M | $-75.1M | $-4.28 | — |
| Q3 2024 | $0.00 | NaN% | $-22.2M | $-20.2M | $-1.19 | — |
| Q2 2024 | $925.0K | 11.7% | $-20.1M | $-18.5M | $-1.09 | — |
| Q1 2024 | $0.00 | -Infinity% | $-18.8M | $-16.9M | $-1.00 | — |
| Q4 2023 | $0.00 | -Infinity% | $-14.7M | $2.4M | $-1.21 | — |
| FY 2023 | $0.00 | -Infinity% | $-55.6M | $-36.3M | $-2.83 | — |